FDA sets late 2024 decision deadline for Pfizer’s 'pan-hemophilia' drug: #ASH23
SAN DIEGO — The FDA is expected to decide whether to approve Pfizer’s hemophilia A and B antibody in the fourth quarter of 2024, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.